ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2834

Assessing the Risk of Gout with Sodium Glucose Co-Transporter-2 Inhibitors: A Population-Based Cohort Study

Michael Fralick1, Sarah Chen 2, Elisabetta Patorno 3 and Seoyoung C. Kim 4, 1Mount Sinai Hospital, University of Toronto, Toronto, 2Brigham and Women's Hospital and Harvard Medical School, Boston, 3Harvard University, Boston, 4Brigham and Women’s Hospital and Harvard Medical School, Boston

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: diabetes and crystal-induced arthritis, gout

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Tuesday, November 12, 2019

Session Title: 5T112: Metabolic & Crystal Arthropathies II: Genetics & Physiology (2834–2839)

Session Type: ACR Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Hyperuricemia is common in patients with type 2 diabetes mellitus and is associated with an increased risk of gout. Sodium-glucose cotransporter 2 (SGLT2) inhibitors, the newest class of medications for adults with diabetes mellitus, promote glycosuria and also lower serum uric acid levels through urinary excretion. The objective of our study was to assess the risk of gout among adults prescribed an SGLT2 inhibitor versus a glucagon-like peptide-1 receptor (GLP1) agonist.

Methods: We conducted a population-based new-user cohort study from March 2013 to December 2017 using claims data from a US nationwide commercial insurance database (IBM MarketScan). Patients with type 2 diabetes mellitus newly prescribed an SGLT2 inhibitor were 1:1 propensity score-matched to patients newly prescribed a GLP1 agonist. Patients were excluded if they had a history of gout or had received gout-specific treatment previously. The primary outcome was new diagnosis of gout based on an inpatient diagnosis of gout or the combination of an outpatient diagnosis and use of a gout-related medication within 14 days thereafter. The rate of heart failure hospitalization (positive control based on the known effect of SGLT2 inhibitor on reducing heart failure) and cellulitis (negative control) were also assessed. Cox proportional hazards regression was used to estimate hazard ratios (HR) of the primary outcome and 95% confidence intervals (CI).

Results: We identified 295,907 adults with type 2 diabetes mellitus who were newly prescribed an SGLT2 inhibitor or a GLP1 agonist. After 1:1 propensity score matching, we identified 111,419 pairs of patients prescribed an SGLT2 inhibitor or GLP1 agonist. The mean age was 54 years, 52% were female, and 26% were prescribed insulin at baseline (Table 1). The incidence rate of gout was lower for patients prescribed an SGLT2 inhibitor (4.9 events per 1,000 person-years) compared to those prescribed a GLP1-agonist (8.1 events per 1,000 person-years), with a HR of 0.61 (95%CI 0.54-0.69) over a median follow-up of 177 days. As anticipated, SGLT2 inhibitor initiators had a lower rate of heart failure (HR 0.63, 95%CI 0.51-0.78) and a similar rate of cellulitis (HR 1.05, 95%CI 1.00-1.11) compared to patients prescribed a GLP1 agonist.

Conclusion: Adults with type 2 diabetes prescribed an SGLT2 inhibitor had a lower rate of gout compared to those prescribed a GLP1 agonist. SGLT2 inhibitors may reduce the risk of developing gout among adults with type 2 diabetes mellitus, though future studies are necessary to confirm this observation.


GRASS_Abstract_Table1


GRASS_Abstract_Table2


Disclosure: M. Fralick, None; S. Chen, None; E. Patorno, Dr. Patorno reports grants from the National Institute on Aging, GlaxoSmithKline, and Boehringer Ingelheim outside the submitted work., 2; S. Kim, AbbVie, 2, AstraZeneca, 2, Bristol-Myers Squibb, 2, Merck, 2, Pfizer, 2, research grants to Brigham and Women’s Hospital from Pfizer, AbbVie, Bristol-Myers Squibb, and Roche for unrelated topics, 2, Roche, 2, Roche/Genentech, 2.

To cite this abstract in AMA style:

Fralick M, Chen S, Patorno E, Kim S. Assessing the Risk of Gout with Sodium Glucose Co-Transporter-2 Inhibitors: A Population-Based Cohort Study [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/assessing-the-risk-of-gout-with-sodium-glucose-co-transporter-2-inhibitors-a-population-based-cohort-study/. Accessed January 21, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/assessing-the-risk-of-gout-with-sodium-glucose-co-transporter-2-inhibitors-a-population-based-cohort-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.